EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins

Brandon C Rosen iD, Jack T Mauter iD, Thomas B Voigt iD, Giovana de Figueiredo Godoy, Emma L Walker iD, Johan J Louw, Noor Ghosh, Christakis Panayiotou, Aaron Yrizarry-Medina, Joshua Terao, Eva G Rakasz iD, Matthew R Reynolds iD und 4 weitere

Viruses · 2026

DOI: 10.3390/v18090981 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Brandon C Rosen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA. Hauptthemen laut MEDLINE: Influenza A Virus, H5N1 Subtype, Antibodies, Viral, Influenza Vaccines, Antibodies, Neutralizing. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, George Washington University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly pathogenic avian influenza (HPAI) represents an enormous pandemic risk amid the ongoing H5N1 panzootic. HPAI, defined by its high lethality in domestic poultry, includes the influenza A virus (IAV) H5N1 and H7N9 subtypes and has a 40–50% case fatality rate in humans. To facilitate the development of efficacious HPAI vaccination regimens and isolation of HPAI-neutralizing monoclonal antibodies (nmAbs) for prophylactic and therapeutic use, we performed a proof-of-concept pilot study wherein we developed an array of mRNA and adenovirus-vectored vaccines encoding HPAI hemagglutinins (HAs) and then assessed their immunogenicity in IAV-naïve Indian rhesus macaques (RMs). All RMs developed binding IgG recognizing both HPAI HAs. HPAI-nAbs were detected in RMs vaccinated with full-length HAs, but not in RMs vaccinated with HA stems alone. Potent HPAI neutralization activity was observed in two animals with serum ID50 titers of ~1:100,000 against H5N1 and ~1:50,000 against H7N9. Most RMs developed cross-reactive IgG recognizing the HAs of additional IAV subtypes, and HA-specific B cells were readily identifiable in vaccinee PBMCs by flow cytometric analysis. The results of our pilot study suggest that elicitation of potent HPAI-nAb responses is enhanced by vaccination with the HA head domain and that vaccination with the HA stem alone tends to elicit binding non-nAbs. Furthermore, use of our fluorophore-conjugated HA probes to identify HA-specific B cells could enable HPAI-nmAb isolation. Collectively, our findings could facilitate the development of novel vaccines and nmAb therapeutics leveraging the superior neutralization potency of HA head-specific Abs to prevent and treat HPAI infections in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H5N1 SubtypeAntibodies, ViralInfluenza VaccinesAntibodies, NeutralizingHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H7N9 SubtypeAnimalsMacaca mulattaVaccinationOrthomyxoviridae InfectionsGenetic VectorsAdenoviridaeRNA, MessengerPilot ProjectsImmunoglobulin G

Stichwörter der Autor:innen

B lymphocytesH5N1H7N9antibodieshighly pathogenic avian influenzainfluenza A virusvaccines

Substanzen

Antibodies, ViralInfluenza VaccinesAntibodies, NeutralizingHemagglutinin Glycoproteins, Influenza VirusRNA, MessengerImmunoglobulin G

Autor:innen und Institutionen

  • Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
  • Medical Scientist Training Program, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
  • Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
  • Mabloc, LLC, Washington, DC 20052, USA.

ORCID-Profile: Brandon C Rosen, Jack T Mauter, Thomas B Voigt, Emma L Walker, Eva G Rakasz, Matthew R Reynolds, Douglas S Reed, Michael J Ricciardi

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • George Washington University
  • National Institute of Allergy and Infectious Diseases
  • NIH

Zitieren

APA

Rosen, B. C., Mauter, J. T., Voigt, T. B., de Figueiredo Godoy, G., Walker, E. L., Louw, J. J., Ghosh, N., Panayiotou, C., Yrizarry-Medina, A., Terao, J., Rakasz, E. G., Reynolds, M. R., Dudley, D. M., Reed, D. S., Watkins, D. I., & Ricciardi, M. J. (2026). Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins. Viruses. https://doi.org/10.3390/v18090981

Vancouver

Rosen BC, Mauter JT, Voigt TB, de Figueiredo Godoy G, Walker EL, Louw JJ, et al. Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins. Viruses. 2026. doi:10.3390/v18090981

BibTeX
@article{Rosen2026,
  author = {Rosen, Brandon C and Mauter, Jack T and Voigt, Thomas B and de Figueiredo Godoy, Giovana and Walker, Emma L and Louw, Johan J and Ghosh, Noor and Panayiotou, Christakis and Yrizarry-Medina, Aaron and Terao, Joshua and Rakasz, Eva G and Reynolds, Matthew R and Dudley, Dawn M and Reed, Douglas S and Watkins, David I and Ricciardi, Michael J},
  title = {Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18090981}
}
Kostenlos starten →